{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:05:06Z","timestamp":1790431506031,"version":"4.1.0"},"publisher-location":"Cham","reference-count":74,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319701950","type":"print"},{"value":"9783319701974","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-70197-4_11","type":"book-chapter","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T23:52:30Z","timestamp":1516319550000},"page":"167-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Sexual Function Post-Breast Cancer"],"prefix":"10.1007","author":[{"given":"Lauren","family":"Streicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,20]]},"reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1080\/08870446.2013.879136","volume":"29","author":"GA Raggio","year":"2014","unstructured":"Raggio GA, Butryn ML, Arigo D, Mikorski R, Palmer SC (2014) Prevalence and correlates of sexual morbidity in long-term breast cancer survivors. Psychol Health 29:632\u2013650","journal-title":"Psychol Health"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/AOG.0b013e3181898cdb","volume":"112","author":"JL Shifren","year":"2008","unstructured":"Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB (2008) Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 112:970\u2013978","journal-title":"Obstet Gynecol"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.breast.2014.06.012","volume":"23","author":"L Aerts","year":"2014","unstructured":"Aerts L, Christiaens MR, Enzlin P, Neven P, Amant F (2014) Sexual functioning in women after mastectomy versus breast conserving therapy for early-stage breast cancer: a prospective controlled study. Breast 23:629\u2013636","journal-title":"Breast"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1245\/s10434-011-1828-7","volume":"19","author":"KA Metcalfe","year":"2012","unstructured":"Metcalfe KA, Semple J, Quan ML, Vadaparampil ST, Holloway C, Brown M et al (2012) Changes in psychosocial functioning 1\u00a0year after mastectomy alone, delayed breast reconstruction, or immediate breast reconstruction. Ann Surg Oncol 19:233\u2013241","journal-title":"Ann Surg Oncol"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jso.23829","volume":"111","author":"KA Metcalfe","year":"2015","unstructured":"Metcalfe KA, Zhong T, Narod SA, Quan ML, Holloway C, Hofer S et al (2015) A prospective study of mastectomy patients with and without delayed breast reconstruction: long-term psychosocial functioning in the breast cancer survivorship period. J Surg Oncol 111:258\u2013264","journal-title":"J Surg Oncol"},{"key":"11_CR6","doi-asserted-by":"publisher","unstructured":"Bennet K, Qi J, Kim H (2017) Association of fat grafting with patient-reported outcomes in post mastectomy breast reconstruction. JAMA Surg. doi: 10.1001\/jamasurg.2017.1716","DOI":"10.1001\/jamasurg.2017.1716"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2016.08.005","volume":"30","author":"PE Tucker","year":"2016","unstructured":"Tucker PE, Saunders C, Bulsara MK, Tan JJ, Salfinger SG, Green H et al (2016) Sexuality and quality of life in women with a prior diagnosis of breast cancer after risk-reducing salpingo-oophorectomy. Breast 30:26\u201331","journal-title":"Breast"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1245\/s10434-014-3483-2","volume":"21","author":"CR Albornoz","year":"2014","unstructured":"Albornoz CR, Matros E, McCarthy CM, Klassen A, Cano SJ, Alderman AK et al (2014) Implant breast reconstruction and radiation: a multicenter analysis of long-term health-related quality of life and satisfaction. Ann Surg Oncol 21:2159\u20132164","journal-title":"Ann Surg Oncol"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","volume":"20","author":"J Baumgart","year":"2013","unstructured":"Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS (2013) Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause 20:162\u2013168","journal-title":"Menopause"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1111\/jsm.12684","volume":"11","author":"LR Schover","year":"2014","unstructured":"Schover LR, Baum GP, Fuson LA, Brewster A, Melhem-Bertrandt A (2014) Sexual problems during the first 2\u00a0years of adjuvant treatment with aromatase inhibitors. J Sex Med 11:3102\u20133111","journal-title":"J Sex Med"},{"issue":"29","key":"11_CR11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1515\/hmbci-2016-0042","volume":"01","author":"F Labrie","year":"2017","unstructured":"Labrie F, Martel C (2017) A low dose (6.5\u00a0mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values. Horm Mol Biol Clin Investig 01(29):39\u201360","journal-title":"Horm Mol Biol Clin Investig"},{"key":"11_CR12","doi-asserted-by":"crossref","unstructured":"Diagnostic and Statistical Manual of Mental Disorders, 5th ed. American Psychiatric Association, Arlington, VA (2013)","DOI":"10.1176\/appi.books.9780890425596"},{"key":"11_CR13","first-page":"425","volume":"73","author":"GA Bachmann","year":"1989","unstructured":"Bachmann GA, Leiblum SR, Grill J (1989) Brief sexual inquiry in gynecologic practice. Obstet Gynecol 73:425\u2013427","journal-title":"Obstet Gynecol"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JCO.2005.05.101","volume":"23","author":"A Katz","year":"2005","unstructured":"Katz A (2005) The sounds of silence: sexuality information for cancer patients. J Clin Oncol 23:238\u2013241","journal-title":"J Clin Oncol"},{"key":"11_CR15","doi-asserted-by":"crossref","unstructured":"Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R et al (2000) The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26:191\u2013208","DOI":"10.1080\/009262300278597"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3322\/caac.21337","volume":"66","author":"ST Lindau","year":"2016","unstructured":"Lindau ST, Abramsohn EM, Baron SR, Florendo J, Haefner HK, Jhingran A et al (2016) Physical examination of the female cancer patient with sexual concerns: what oncologists and patients should expect from consultation with a specialist. CA Cancer J Clin 66:241\u2013263","journal-title":"CA Cancer J Clin"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.maturitas.2014.07.013","volume":"79","author":"DJ Portman","year":"2014","unstructured":"Portman DJ, Gass ML (2014) Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society. Maturitas 79:349\u2013354","journal-title":"Maturitas"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/AOG.0b013e31828786f8","volume":"121","author":"JM Brown","year":"2013","unstructured":"Brown JM, Hess KL, Brown S, Murphy C, Waldman AL, Hezareh M (2013) Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States. Obstet Gynecol 121:773\u2013780","journal-title":"Obstet Gynecol"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/AAC.01151-09","volume":"54","author":"KL Strandberg","year":"2010","unstructured":"Strandberg KL, Peterson ML, Lin YC, Pack MC, Chase DJ, Schlievert PM (2010) Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. Antimicrob Agents Chemother 54:597\u2013601","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jcp.55.6.446","volume":"55","author":"JA Laak van der","year":"2002","unstructured":"van der Laak JA, de Bie LM, de Leeuw H, de Wilde PC, Hanselaar AG (2002) The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol 55:446\u2013451","journal-title":"J Clin Pathol"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/jsm.12125","volume":"10","author":"J Chen","year":"2013","unstructured":"Chen J, Geng L, Song X, Li H, Giordan N, Liao Q (2013) Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med 10:1575\u20131584","journal-title":"J Sex Med"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/GME.0000000000000316","volume":"21","author":"JE Manson","year":"2014","unstructured":"Manson JE, Goldstein SR, Kagan R, Kaunitz AM, Liu JH, Pinkerton JV et al (2014) Why the product labeling for low-dose vaginal estrogen should be changed. Menopause 21:911\u2013916","journal-title":"Menopause"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","volume":"18","author":"RJ Santen","year":"2015","unstructured":"Santen RJ (2015) Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 18:121\u2013134","journal-title":"Climacteric"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.maturitas.2015.07.020","volume":"82","author":"S Palacios","year":"2015","unstructured":"Palacios S, Castelo-Branco C, Currie H, Mijatovic V, Nappi RE, Simon J et al (2015) Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas 82:308\u2013313","journal-title":"Maturitas"},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/13697137.2010.522875","volume":"13","author":"DW Sturdee","year":"2010","unstructured":"Sturdee DW, Panay N (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13:509\u2013522","journal-title":"Climacteric"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","volume":"93","author":"ES O\u2019Meara","year":"2001","unstructured":"O\u2019Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93:754\u2013762","journal-title":"J Natl Cancer Inst"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/AOG.0000000000001351","volume":"127","author":"ACOG Committee Opinion: Number 659","year":"2016","unstructured":"ACOG Committee Opinion: Number 659 (2016) The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 127:e93\u2013e96","journal-title":"Obstet Gynecol"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","volume":"135","author":"I Ray Le","year":"2012","unstructured":"Le Ray I, Dell\u2019Aniello S, Bonnetain F, Azoulay L, Suissa S (2012) Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 135:603\u2013609","journal-title":"Breast Cancer Res Treat"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.ejca.2005.07.015","volume":"41","author":"R Ponzone","year":"2005","unstructured":"Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P (2005) Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 41:2673\u20132681","journal-title":"Eur J Cancer"},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1634\/theoncologist.2007-0234","volume":"13","author":"M Trinkaus","year":"2008","unstructured":"Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M (2008) Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 13:222\u2013231","journal-title":"Oncologist"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","volume":"8","author":"S Wills","year":"2012","unstructured":"Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M et al (2012) Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 8:144\u2013148","journal-title":"J Oncol Pract"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/13543780902953715","volume":"18","author":"L Gennari","year":"2009","unstructured":"Gennari L, Merlotti D, Valleggi F, Nuti R (2009) Ospemifene use in postmenopausal women. Expert Opin Investig Drugs 18:839\u2013849","journal-title":"Expert Opin Investig Drugs"},{"key":"11_CR33","first-page":"370","volume":"69","author":"RE Nappi","year":"2017","unstructured":"Nappi RE, Murina F, Perrone G, Villa P, Biglia N (2017) Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol 69:370\u2013380","journal-title":"Minerva Ginecol"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.maturitas.2013.12.005","volume":"77","author":"J Simon","year":"2014","unstructured":"Simon J, Portman D, Mabey RG Jr (2014) Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas 77:274\u2013281","journal-title":"Maturitas"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","volume":"20","author":"JA Simon","year":"2013","unstructured":"Simon JA, Lin VH, Radovich C, Bachmann GA (2013) One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 20:418\u2013427","journal-title":"Menopause"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2014.02.015","volume":"78","author":"D Portman","year":"2014","unstructured":"Portman D, Palacios S, Nappi RE, Mueck AO (2014) Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 78:91\u201398","journal-title":"Maturitas"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13697137.2013.834493","volume":"17","author":"SR Goldstein","year":"2014","unstructured":"Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O (2014) Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 17:173\u2013182","journal-title":"Climacteric"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/1933719113497290","volume":"20","author":"SL Berga","year":"2013","unstructured":"Berga SL (2013) Profile of ospemifene in the breast. Reprod Sci 20:1130\u20131136","journal-title":"Reprod Sci"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/GME.0000000000000571","volume":"23","author":"F Labrie","year":"2016","unstructured":"Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L et al (2016) Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 23:243\u2013256","journal-title":"Menopause"},{"key":"11_CR40","unstructured":"Kaufman MB (2017) Pharmaceutical approval update. P T 42:90\u201391"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/gme.0b013e3181e195a6","volume":"18","author":"F Labrie","year":"2011","unstructured":"Labrie F, Martel C, Balser J (2011) Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 18:30\u201343","journal-title":"Menopause"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jsbmb.2016.03.016","volume":"159","author":"C Martel","year":"2016","unstructured":"Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN et al (2016) Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5\u00a0mg intravaginal prasterone for 12weeks. J Steroid Biochem Mol Biol 159:142\u2013153","journal-title":"J Steroid Biochem Mol Biol"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/jpm5020050","volume":"5","author":"J Lester","year":"2015","unstructured":"Lester J, Pahouja G, Andersen B, Lustberg M (2015) Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue. J Personalized Med 5:50\u201366","journal-title":"J Personalized Med"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10103-014-1677-2","volume":"30","author":"N Zerbinati","year":"2015","unstructured":"Zerbinati N, Serati M, Origoni M, Candiani M, Iannitti T, Salvatore S et al (2015) Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci 30:429\u2013436","journal-title":"Lasers Med Sci"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/GME.0000000000000700","volume":"23","author":"ER Sokol","year":"2016","unstructured":"Sokol ER, Karram MM (2016) An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause 23:1102\u20131107","journal-title":"Menopause"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2014.975197","volume":"18","author":"S Salvatore","year":"2015","unstructured":"Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N et al (2015) Sexual function after fractional microablative CO(2) laser in women with vulvovaginal atrophy. Climacteric 18:219\u2013225","journal-title":"Climacteric"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/GME.0000000000000839","volume":"24","author":"ER Sokol","year":"2016","unstructured":"Sokol ER, Karram MM (2016) Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes. Menopause 24:810\u2013814","journal-title":"Menopause"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/jsm.13056","volume":"12","author":"RE Pyke","year":"2015","unstructured":"Pyke RE, Clayton AH (2015) Psychological treatment trials for hypoactive sexual desire disorder: a sexual medicine critique and perspective. J Sex Med 12:2451\u20132458","journal-title":"J Sex Med"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-015-0288-1","volume":"29","author":"SA Kingsberg","year":"2015","unstructured":"Kingsberg SA, Clayton AH, Pfaus JG (2015) The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs 29:915\u2013933","journal-title":"CNS Drugs"},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1111\/j.1743-6109.2009.01294.x","volume":"6","author":"MC Snabes","year":"2009","unstructured":"Snabes MC, Simes SM (2009) Approved hormonal treatments for HSDD: an unmet medical need. J Sex Med 6:1846\u20131849","journal-title":"J Sex Med"},{"key":"11_CR51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/smrj.53","volume":"3","author":"M Khera","year":"2015","unstructured":"Khera M (2015) Testosterone therapy for female sexual dysfunction. Sex Med Rev 3:137\u2013144","journal-title":"Sex Med Rev"},{"key":"11_CR52","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1210\/jc.2014-2260","volume":"99","author":"ME Wierman","year":"2014","unstructured":"Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH et al (2014) Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99:3489\u20133510","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR53","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/01.AOG.0000158103.27672.0d","volume":"105","author":"JE Buster","year":"2005","unstructured":"Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A et al (2005) Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 105:944\u2013952","journal-title":"Obstet Gynecol"},{"issue":"Suppl 3","key":"11_CR54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1743-6109.2007.00449.x","volume":"4","author":"S Kingsberg","year":"2007","unstructured":"Kingsberg S (2007) Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women. J Sex Med 4(Suppl 3):227\u2013234","journal-title":"J Sex Med"},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/archinte.165.14.1582","volume":"165","author":"GD Braunstein","year":"2005","unstructured":"Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA et al (2005) Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 165:1582\u20131589","journal-title":"Arch Intern Med"},{"key":"11_CR56","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1210\/jc.2004-1747","volume":"90","author":"J Simon","year":"2005","unstructured":"Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S et al (2005) Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90:5226\u20135233","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR57","doi-asserted-by":"crossref","unstructured":"Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L et al (2006) Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 13:770\u2013779","DOI":"10.1097\/01.gme.0000227400.60816.52"},{"key":"11_CR58","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa0707302","volume":"359","author":"SR Davis","year":"2008","unstructured":"Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M et al (2008) Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 359:2005\u20132017","journal-title":"N Engl J Med"},{"key":"11_CR59","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1188\/17.ONF.296-301","volume":"44","author":"EA Lemke","year":"2017","unstructured":"Lemke EA, Madsen LT, Dains JE (2017) Vaginal testosterone for management of aromatase inhibitor-related sexual dysfunction: an integrative review. Oncol Nurs Forum 44:296\u2013301","journal-title":"Oncol Nurs Forum"},{"key":"11_CR60","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/sm2.22","volume":"2","author":"M Dahir","year":"2014","unstructured":"Dahir M, Travers-Gustafson D (2014) Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapy. Sex Med 2:8\u201315","journal-title":"Sex Med"},{"key":"11_CR61","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","volume":"16","author":"S Witherby","year":"2011","unstructured":"Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD et al (2011) Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study. Oncologist 16:424\u2013431","journal-title":"Oncologist"},{"key":"11_CR62","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1743-6109.2009.01309.x","volume":"6","author":"JG Pfaus","year":"2009","unstructured":"Pfaus JG (2009) Pathways of sexual desire. J Sex Med 6:1506\u20131533","journal-title":"J Sex Med"},{"key":"11_CR63","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.neuroscience.2008.09.044","volume":"158","author":"BA Arnow","year":"2009","unstructured":"Arnow BA, Millheiser L, Garrett A, Lake Polan M, Glover GH, Hill KR et al (2009) Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience 158:484\u2013502","journal-title":"Neuroscience"},{"key":"11_CR64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1743-6109.2010.02032.x","volume":"8","author":"SM Stahl","year":"2011","unstructured":"Stahl SM, Sommer B, Allers KA (2011) Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 8:15\u201327","journal-title":"J Sex Med"},{"key":"11_CR65","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/GME.0000000000000134","volume":"21","author":"JA Simon","year":"2013","unstructured":"Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M (2013) Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 21:633\u2013640","journal-title":"Menopause"},{"key":"11_CR66","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1743-6109.2011.02626.x","volume":"9","author":"LR Derogatis","year":"2012","unstructured":"Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr et al (2012) Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med 9:1074\u20131085","journal-title":"J Sex Med"},{"key":"11_CR67","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1743-6109.2011.02595.x","volume":"9","author":"J Thorp","year":"2012","unstructured":"Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr et al (2012) Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 9:793\u2013804","journal-title":"J Sex Med"},{"key":"11_CR68","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/jsm.12189","volume":"10","author":"M Katz","year":"2013","unstructured":"Katz M, DeRogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr et al (2013) Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 10:1807\u20131815","journal-title":"J Sex Med"},{"key":"11_CR69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJMp1513686","volume":"374","author":"HV Joffe","year":"2016","unstructured":"Joffe HV, Chang C, Sewell C, Easley O, Nguyen C, Dunn S et al (2016) fda approval of flibanserin-treating hypoactive sexual desire disorder. N Engl J Med 374:101\u2013104","journal-title":"N Engl J Med"},{"key":"11_CR70","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.2003.tb03167.x","volume":"994","author":"PB Molinoff","year":"2003","unstructured":"Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY (2003) PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann NY Acad Sci 994:96\u2013102","journal-title":"Ann NY Acad Sci"},{"key":"11_CR71","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1743-6109.2006.00268.x","volume":"3","author":"LE Diamond","year":"2006","unstructured":"Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R (2006) An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 3:628\u2013638","journal-title":"J Sex Med"},{"key":"11_CR72","doi-asserted-by":"crossref","unstructured":"Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I et al (2016) Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 12:325\u2013337","DOI":"10.2217\/whe-2016-0018"},{"key":"11_CR73","doi-asserted-by":"crossref","unstructured":"Abstracts of the ACOG (American College of Obstetricians and Gynecologists) (2008) 56th annual clinical meeting. May 3\u20137, 2008. New Orleans, Louisiana, USA. Obstet Gynecol 111:1S\u2013113S","DOI":"10.1097\/AOG.0b013e3181636fe9"},{"key":"11_CR74","unstructured":"Bremelanotide Meets Co-Primary Endpoints in Palatin\u2019s Phase 3 Trials for Hypoactive Sexual Desire Disorder. Available at: http:\/\/www.prnewswire.com\/news-releases\/bremelanotide-meets-co-primary-endpoints-in-palatins-phase-3-trials-for-hypoactive-sexual-desire-disorder-300355401.html [cited 2017 01\/29\/2017]"}],"container-title":["Cancer Treatment and Research","Optimizing Breast Cancer Management"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-70197-4_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T16:13:57Z","timestamp":1719764037000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-70197-4_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319701950","9783319701974"],"references-count":74,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-70197-4_11","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}